Content Object
(
    [className] => Content
    [contentLinks] => Array
        (
        )

    [belongsTo] => 
    [contentIssue] => 
    [id] => 311669
    [pageNumber] => 
    [offset] => 
    [totalPages] => 
    [last_query] => 
    [last_sql] => 
    [show_errors] => 1
    [databaseServer] => Array
        (
            [key] => master
            [host] => 172.24.16.232
            [user] => rodpub_beta
            [pass] => MvQQzhse92k58yA
            [db] => rodpub_beta
        )

    [tableName] => contents
    [content_type_id] => 2487
    [resource_id] => 0
    [author_id] => 0
    [primary_issue_slug] => 
    [author_name] => {"name":"Business Wire","title":""}
    [magazine_id] => 6
    [layout_id] => 0
    [primary_image] => 186303
    [primary_image_old] => 
    [slider_image_id] => 186303
    [banner_image] => 0
    [title] => Seisa Medical Acquires Burpee MedSystems
    [short_title] => 
    [summary] =>  New Jersey-based Burpee MedSystems is a manufacturer of stents and delivery devices.
    [slug] => seisa-medical-acquires-burpee-medsystems
    [body] => Seisa Medical Inc., a full-service provider of integrated manufacturing and development services to the medical device industry, has acquired Burpee MedSystems LLC, a manufacturer of stents and delivery devices.
 
“This acquisition demonstrates Seisa’s commitment to investing in vertical capabilities to create end-to-end solutions that deliver value to our customers,” said Julio Chiu, founder and CEO of Seisa Medical. “The marriage between Seisa’s high-volume production of FDA Class II and Class III devices with Burpee MedSystems’ mastery in the manufacture of complex stents, delivery systems, and components will provide a scalable one-stop-shop for customers focused on the high-growth markets for implantable stents and their delivery systems.”
 
Burpee MedSystems was founded in 1998 by Janet and Steve Burpee, who leveraged their deep knowledge in design, mechanical engineering, chemical engineering, and metallurgy to build Burpee MedSystems into a highly technical team of engineers and technicians with a strong reputation for quality and innovation in the development and production of stents and delivery systems. The team is highly skilled in laser machining, surface finishing, nitinol forming and shaping, and welding. The Burpee team also has deep, collective experience in formulating and implementing regulatory strategies and study designs to help guide customers along the path from concept to FDA approval.
 
Janet Burpee, CEO and co-founder of New Jersey-based Burpee MedSystems added, “We are thrilled to be joining Seisa as it gives Burpee MedSystems the global infrastructure we’ve been aiming for to expand our offerings and capabilities to the market.”
 
Janet and Steve Burpee will continue supporting the Burpee team and retain majority ownership of Tinker Med, LLC—a medical device incubator and holding company previously wholly owned by Burpee MedSystems.
 
Seisa funded the transaction through its $52 million senior secured credit facility with Sagard Credit Partners. Seisa continues to actively pursue prudent and accretive acquisitions that add capability and geographic scope to the Texas-based company.
 
“We are excited to welcome the Burpee team to Seisa,” said Chiu. “Together we offer not only a compelling offering for strategic outsourcing solutions in the medical device market but also provide all our employees more opportunities globally as well.” [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-04-05 14:15:00 [updated_at] => 2019-04-05 14:20:05 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["311673","311491","311395","311006","310992","310355","309564","309243","309187","308446","310636","309544","308551","308542","307672","307577","306990","305917","305910","305608"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 [contentType] => ContentType Object ( [className] => ContentType [content] => Array ( ) [taxonomy] => Array ( ) [listURL] => [logoUrl] => https: [id] => 2487 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => content_types [tag] => breaking_news [short_tag] => breaking_news [class_name] => [display_view] => [list_view] => [slug] => breaking-news [box_view] => [ignore_flag] => 0 [image_id] => 0 [layout_id] => 0 [formattedTag] => Breaking News ) [viewURL] => /contents/view_breaking-news/2019-04-05/seisa-medical-acquires-burpee-medsystems/ [relatedArticles] => Array ( [0] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305608 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180659 [primary_image_old] => [slider_image_id] => 180659 [banner_image] => 0 [title] => Cantel Acquires Vista Research Group [short_title] => [summary] => Enhances Cantel's Dental water solutions portfolio and advances global leadership position in infection prevention. [slug] => cantel-acquires-vista-research-group [body] => Cantel Medical Corp. announced that it has acquired Vista Research Group, LLC. ("Vista Research Group"), a company that provides a complete line of innovative water treatment, purification and management solutions for the dental industry. The total purchase price was approximately $10.5 million in cash consideration, consisting of $7 million in an upfront payment and $3.5 million in an earnout payment based on the achievement of certain performance-based targets over a two-year period. Total sales of Vista Research Group in 2018 were approximately $2.0 million.
 
Vista Research Group has an innovative portfolio of solutions for filtration, purification, treatment, and management of dental water to reduce the risk of infections, improve patient care, enhance practice workflow, and protect dental equipment.
 
"We're excited that Vista Research Group is now part of Cantel. The integration of their water treatment technologies into our existing portfolio allows us to offer our customers more comprehensive infection prevention solutions that provide clean water across all touchpoints in the dental clinic," stated Jorgen Hansen, president and CEO. "This acquisition also reinforces our position as the market leader in dental water compliance."
 
"The addition of Vista Research Group's solutions will broaden our dental water purification portfolio and advance the development of our product line. In addition to our DentaPure Cartridge, it also will enable us to provide a full suite of end-to-end dental water compliance solutions to dental practices," said Gary Steinberg, president of Cantel's Dental division. "In our ongoing commitment to infection prevention and compliance, we look forward to driving the awareness of and access to the VistaPure, VistaCool, and VistaClear products so more dental practices can benefit from improved efficiency, simplified workflows, and better protection for both patients and staff." [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-11 09:08:00 [updated_at] => 2019-01-11 09:12:58 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["291203","302241","305409","305174","304388","304187","304105","303297","302686","301744","300716"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [1] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305910 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"Abbott Laboratories","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180944 [primary_image_old] => [slider_image_id] => 180944 [banner_image] => 0 [title] => Abbott to Acquire Cephea Valve Technologies [short_title] => [summary] => Acquisition to further bolster Abbott's position in therapies for mitral valve disease, the most common type of heart valve ailment. [slug] => abbott-to-acquire-cephea-valve-technologies [body] => Abbott announced that it has exercised its option to purchase Cephea Valve Technologies Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015.
 
Cephea's technology is being developed to provide an option for people whose diseased mitral valves need to be replaced. The artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of the diseased mitral valve restores normal blood flow through the heart.
 
"The acquisition of Cephea builds on Abbott's strong position in structural heart therapies and is consistent with our strategy to develop comprehensive treatments for people with mitral valve disease," said Michael Dale, vice president of Abbott's structural heart business. "Cephea's novel approach to replace the mitral valve adds to our other catheter-based technologies and is being developed to provide an additional option for patients who suffer from this difficult-to-treat disease."
 
Mitral valve disease is the most common heart valve problem, affecting more than 4 million people in the U.S. alone. It comes in two forms: regurgitation, a condition where blood leaks backward into the heart, or, less commonly, stenosis, a narrowing of the valve. The condition puts people at risk for health complications such as irregular heartbeats, high blood pressure, blood clots or heart failure.
 
Abbott has led the development of minimally invasive solutions for mitral valve disease since 2009 when it acquired Evalve Inc., with its MitraClip technology. MitraClip, the first-of-its-kind product to repair leaky heart valves, launched in Europe in 2008 and the U.S. in 2013 and remains the only mitral valve repair device of its kind on the market.
 
In 2015, Abbott expanded its portfolio by acquiring Tendyne Holdings Inc. and securing an option to acquire Cephea Valve Technologies, companies that are both developing minimally invasive devices intended to fully replace the mitral valve in the heart. Minimally invasive mitral valve procedures are expected to become a multi-billion-dollar market in the coming years. In addition, Abbott acquired St. Jude Medical in 2017, adding to the company's expertise and offerings to treat structural heart disease. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-16 10:00:00 [updated_at] => 2019-01-16 10:26:28 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["304464","305696","300780","300499","300283","299288","290449","290175","289559","296226","289764","305917","305608","305409","305174","304187","304105","303297","302686","300716","300322"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [2] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305917 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180946 [primary_image_old] => [slider_image_id] => 180946 [banner_image] => 0 [title] => Biocoat Inc. Acquired by 1315 Capital [short_title] => [summary] => Specialty manufacturer of hydrophilic biomaterial coatings for medical devices has been acquired by healthcare growth investment firm. [slug] => biocoat-inc-acquired-by-1315-capital [body] => Biocoat Inc., a 27-year old privately held company, announced that it has been acquired by 1315 Capital, a Philadelphia-based healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty pharmaceutical companies.  The transaction closed on December 20, 2018.
 
The acquisition of Biocoat by 1315 Capital will assist the company in taking a more aggressive and growth-oriented approach in the biomaterial coatings market for medical devices, a market projected to reach over $15 billion by 2021.
 
"We're excited about this merger and the financial support which 1315 Capital provides. The synergies between our management team and the team at 1315 Capital were clear from the start," said Jim Moran, president and CEO of Biocoat. "Their investment and operating teams bring an outstanding track record of providing strategic support and expertise, thereby enabling Biocoat to pursue a more aggressive approach to the market."
 
Biocoat specializes in supplying lubricious hydrophilic coatings for medical devices used in the neurovascular, cardiovascular, peripheral, and ophthalmic markets to original equipment manufacturers and contract manufacturers.
 
"Biocoat's combination of differentiated technology within an expanding market and growth-focused management team makes it a great fit for 1315 Capital and we're excited to be working with Jim and his team," stated Michael Koby, Co-Founding Partner, 1315 Capital.
 
Scott Cramer, Chairman of Biocoat added, "Biocoat's HYDAK technologies offer extremely low particulate counts, high lubricity, and low friction, and this merger allows Biocoat to further increase research and development efforts while expanding the operating model to serve a broader range of customers."   [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-16 10:29:00 [updated_at] => 2019-01-16 10:36:09 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["115491","305910","305608","305409","305174","304187","304105","303297","302686","300728","300716","297145","300535","302068","302198","288422"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [3] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 306990 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"Prosek Partners","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 182007 [primary_image_old] => [slider_image_id] => 182007 [banner_image] => 0 [title] => Vance Street Capital Acquires Applied Plastics [short_title] => [summary] => The transaction represents the fourth medtech investment in Fund II and expands the portfolio to six companies. [slug] => vance-street-capital-acquires-applied-plastics [body] => Vance Street Capital LLC, a Los Angeles-based private equity firm, today announced the acquisition of Applied Plastics, an advanced coatings provider to the medical end markets. This is Vance Street’s sixth investment out of Vance Street Capital II L.P. and its fourth investment in the medical space in the past three years. Terms of the transaction were not disclosed.
 
Founded in 1953 and headquartered in Norwood, Mass., Applied provides specialty PTFE coatings on wires and other metal-based components for the medical device industry, with a primary emphasis on the advanced catheter market. Applied’s customers include the leading medical device OEMs and contract manufacturers focused on high-growth microcatheter segments such as electrophysiology (EP), neurovascular, peripheral vascular, TAVR and neuromodulation, among others.
 
Dave Ring, CEO of Applied, is retaining a material ownership position in the company. “We are excited to partner with Vance Street as we look toward our next chapter of growth,” said Mr. Ring. “Vance Street’s highly relevant investing and operating experience in the medical manufacturing space made them the ideal partner to help Applied execute on the exciting growth we see across our customer base.”
 
Brian Martin, Managing Partner at Vance Street, commented, “Dave Ring has built an industry leading and highly differentiated business that is well positioned across the fastest growing medical end markets. We’re excited to support the Applied team during this next chapter of growth.”
 
Vance Street Capital’s other medical investments in Fund II include Motion Dynamics, a leading manufacturer of wire-based micro-components and sub-assemblies found in micro-catheters, Adam Spence Vascular Solutions, a designer and manufacturer of high pressure braided tubing and extrusions for the cardiovascular end markets and A&E Medical, a leading medical device OEM focused on single-use products used in cardiovascular procedures.
 
“Applied Plastics is an ideal opportunity for Vance Street to leverage our operating experience and network within medical manufacturing to continue to build on the world-class and highly-proprietary coatings capabilities Applied has built over the past 25 years,” said Mike Janish, Managing Partner at Vance Street.
 
“We’ve known and admired Applied since our prior involvement with Avalon Laboratories, a medical vascular catheter manufacturer, and are thrilled to have the opportunity to partner with a best in class supplier to the medical catheter industry,” said John LeRosen, Partner at Vance Street.
 
Paul Hastings LLP acted as legal advisor to Vance Street Capital. Senior debt was provided by BMO Sponsor Finance and Neuberger Berman. Raymond James and Sullivan & Worcester LLP served as financial advisor and legal advisor, respectively, to Applied. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-31 10:14:00 [updated_at] => 2019-01-31 10:25:17 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["305917","305910","305608","305409","305174","304187","304105","303297","302686","300728","298721","296461","300632","300394","290585"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [4] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 307577 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 182612 [primary_image_old] => [slider_image_id] => 182612 [banner_image] => 0 [title] => Francisco Partners Acquires Qualcomm Life [short_title] => [summary] => Acquisition positions standalone company to focus on growth opportunities. [slug] => francisco-partners-acquires-qualcomm-life [body] => Francisco Partners ("FP"), a technology-focused private equity firm, today announced it has acquired Qualcomm Life Inc. a wholly owned subsidiary of Qualcomm Incorporated that offers end-to-end medical device connectivity across the continuum of care.
 
Qualcomm Life will be separated from Qualcomm, be renamed as Capsule Technologies Inc. ("CapsuleTech"), and continue operating its two distinct business segments: Capsule (a leading provider of medical device connectivity solutions for hospitals) and 2net (a medical grade mobile connectivity platform).
 
"Francisco Partners' deep experience in healthcare technology and proven track record in nurturing and growing technology businesses will enable CapsuleTech's loyal base of employees to continue delivering innovation," said Duane Nelles, Senior Vice President of Corporate Development at Qualcomm Incorporated. "We look forward to our partnership with the FP team as they grow CapsuleTech as an independent entity."
 
"FP's acquisition will help Qualcomm Life (now CapsuleTech) continue to deliver market-leading products and services to its world-class customer base," said Rick Valencia, former President of Qualcomm Life, who will support CapsuleTech as an advisor in its transition to a standalone company.
 
Capsule is a leading medical device connectivity platform that connects medical devices to clinical information systems in over 2,000 hospitals in approximately 40 countries. Through Capsule's connected devices, networking solutions, and intelligent software applications, hospitals can capture and visualize clinical data to monitor patient health and improve patient care.
 
"Capsule is a key enabler of the digital hospital and is a trusted choice among hospital clinicians, IT administrators, and healthcare IT vendors," said Chris Adams, Partner with Francisco Partners. "As hospitals continue to adopt data-driven approaches to managing patient care, Capsule stands to benefit by serving as a centralized connectivity hub for clinical information. We are excited to partner with Capsule and to help the team capitalize on new innovations in device technology and software applications."
 
2net provides wireless mobile device connectivity via cloud-based solutions so biometric information is easily accessible by device users, healthcare providers, and payors. 2net's customers include leading health insurance payors, pharmaceutical companies, and medical device manufacturers.
 
"Capsule and 2net will continue to drive increased focus on their respective customers, deliver mission-critical solutions and provide exceptional service," said Justin Chen, Vice President with Francisco Partners. "We look forward to supporting the talented employees and management team going forward."
 
Centerview Partners served as financial advisor and DLA Piper LLP served as legal advisor to Qualcomm Incorporated. Kirkland & Ellis LLP served as legal advisor to Francisco Partners. Terms of the transaction were not disclosed. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-02-11 09:29:00 [updated_at] => 2019-02-11 09:48:21 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["304187","298715","306990","305917","305910","305608","305409","305174","304105","303297","302686","294222","307191","294052","306705","301747"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) ) [relatedContent] => Array ( [0] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305608 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180659 [primary_image_old] => [slider_image_id] => 180659 [banner_image] => 0 [title] => Cantel Acquires Vista Research Group [short_title] => [summary] => Enhances Cantel's Dental water solutions portfolio and advances global leadership position in infection prevention. [slug] => cantel-acquires-vista-research-group [body] => Cantel Medical Corp. announced that it has acquired Vista Research Group, LLC. ("Vista Research Group"), a company that provides a complete line of innovative water treatment, purification and management solutions for the dental industry. The total purchase price was approximately $10.5 million in cash consideration, consisting of $7 million in an upfront payment and $3.5 million in an earnout payment based on the achievement of certain performance-based targets over a two-year period. Total sales of Vista Research Group in 2018 were approximately $2.0 million.
 
Vista Research Group has an innovative portfolio of solutions for filtration, purification, treatment, and management of dental water to reduce the risk of infections, improve patient care, enhance practice workflow, and protect dental equipment.
 
"We're excited that Vista Research Group is now part of Cantel. The integration of their water treatment technologies into our existing portfolio allows us to offer our customers more comprehensive infection prevention solutions that provide clean water across all touchpoints in the dental clinic," stated Jorgen Hansen, president and CEO. "This acquisition also reinforces our position as the market leader in dental water compliance."
 
"The addition of Vista Research Group's solutions will broaden our dental water purification portfolio and advance the development of our product line. In addition to our DentaPure Cartridge, it also will enable us to provide a full suite of end-to-end dental water compliance solutions to dental practices," said Gary Steinberg, president of Cantel's Dental division. "In our ongoing commitment to infection prevention and compliance, we look forward to driving the awareness of and access to the VistaPure, VistaCool, and VistaClear products so more dental practices can benefit from improved efficiency, simplified workflows, and better protection for both patients and staff." [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-11 09:08:00 [updated_at] => 2019-01-11 09:12:58 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["291203","302241","305409","305174","304388","304187","304105","303297","302686","301744","300716"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [1] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305910 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"Abbott Laboratories","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180944 [primary_image_old] => [slider_image_id] => 180944 [banner_image] => 0 [title] => Abbott to Acquire Cephea Valve Technologies [short_title] => [summary] => Acquisition to further bolster Abbott's position in therapies for mitral valve disease, the most common type of heart valve ailment. [slug] => abbott-to-acquire-cephea-valve-technologies [body] => Abbott announced that it has exercised its option to purchase Cephea Valve Technologies Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015.
 
Cephea's technology is being developed to provide an option for people whose diseased mitral valves need to be replaced. The artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of the diseased mitral valve restores normal blood flow through the heart.
 
"The acquisition of Cephea builds on Abbott's strong position in structural heart therapies and is consistent with our strategy to develop comprehensive treatments for people with mitral valve disease," said Michael Dale, vice president of Abbott's structural heart business. "Cephea's novel approach to replace the mitral valve adds to our other catheter-based technologies and is being developed to provide an additional option for patients who suffer from this difficult-to-treat disease."
 
Mitral valve disease is the most common heart valve problem, affecting more than 4 million people in the U.S. alone. It comes in two forms: regurgitation, a condition where blood leaks backward into the heart, or, less commonly, stenosis, a narrowing of the valve. The condition puts people at risk for health complications such as irregular heartbeats, high blood pressure, blood clots or heart failure.
 
Abbott has led the development of minimally invasive solutions for mitral valve disease since 2009 when it acquired Evalve Inc., with its MitraClip technology. MitraClip, the first-of-its-kind product to repair leaky heart valves, launched in Europe in 2008 and the U.S. in 2013 and remains the only mitral valve repair device of its kind on the market.
 
In 2015, Abbott expanded its portfolio by acquiring Tendyne Holdings Inc. and securing an option to acquire Cephea Valve Technologies, companies that are both developing minimally invasive devices intended to fully replace the mitral valve in the heart. Minimally invasive mitral valve procedures are expected to become a multi-billion-dollar market in the coming years. In addition, Abbott acquired St. Jude Medical in 2017, adding to the company's expertise and offerings to treat structural heart disease. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-16 10:00:00 [updated_at] => 2019-01-16 10:26:28 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["304464","305696","300780","300499","300283","299288","290449","290175","289559","296226","289764","305917","305608","305409","305174","304187","304105","303297","302686","300716","300322"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [2] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 305917 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 180946 [primary_image_old] => [slider_image_id] => 180946 [banner_image] => 0 [title] => Biocoat Inc. Acquired by 1315 Capital [short_title] => [summary] => Specialty manufacturer of hydrophilic biomaterial coatings for medical devices has been acquired by healthcare growth investment firm. [slug] => biocoat-inc-acquired-by-1315-capital [body] => Biocoat Inc., a 27-year old privately held company, announced that it has been acquired by 1315 Capital, a Philadelphia-based healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty pharmaceutical companies.  The transaction closed on December 20, 2018.
 
The acquisition of Biocoat by 1315 Capital will assist the company in taking a more aggressive and growth-oriented approach in the biomaterial coatings market for medical devices, a market projected to reach over $15 billion by 2021.
 
"We're excited about this merger and the financial support which 1315 Capital provides. The synergies between our management team and the team at 1315 Capital were clear from the start," said Jim Moran, president and CEO of Biocoat. "Their investment and operating teams bring an outstanding track record of providing strategic support and expertise, thereby enabling Biocoat to pursue a more aggressive approach to the market."
 
Biocoat specializes in supplying lubricious hydrophilic coatings for medical devices used in the neurovascular, cardiovascular, peripheral, and ophthalmic markets to original equipment manufacturers and contract manufacturers.
 
"Biocoat's combination of differentiated technology within an expanding market and growth-focused management team makes it a great fit for 1315 Capital and we're excited to be working with Jim and his team," stated Michael Koby, Co-Founding Partner, 1315 Capital.
 
Scott Cramer, Chairman of Biocoat added, "Biocoat's HYDAK technologies offer extremely low particulate counts, high lubricity, and low friction, and this merger allows Biocoat to further increase research and development efforts while expanding the operating model to serve a broader range of customers."   [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-16 10:29:00 [updated_at] => 2019-01-16 10:36:09 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["115491","305910","305608","305409","305174","304187","304105","303297","302686","300728","300716","297145","300535","302068","302198","288422"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [3] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 306990 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"Prosek Partners","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 182007 [primary_image_old] => [slider_image_id] => 182007 [banner_image] => 0 [title] => Vance Street Capital Acquires Applied Plastics [short_title] => [summary] => The transaction represents the fourth medtech investment in Fund II and expands the portfolio to six companies. [slug] => vance-street-capital-acquires-applied-plastics [body] => Vance Street Capital LLC, a Los Angeles-based private equity firm, today announced the acquisition of Applied Plastics, an advanced coatings provider to the medical end markets. This is Vance Street’s sixth investment out of Vance Street Capital II L.P. and its fourth investment in the medical space in the past three years. Terms of the transaction were not disclosed.
 
Founded in 1953 and headquartered in Norwood, Mass., Applied provides specialty PTFE coatings on wires and other metal-based components for the medical device industry, with a primary emphasis on the advanced catheter market. Applied’s customers include the leading medical device OEMs and contract manufacturers focused on high-growth microcatheter segments such as electrophysiology (EP), neurovascular, peripheral vascular, TAVR and neuromodulation, among others.
 
Dave Ring, CEO of Applied, is retaining a material ownership position in the company. “We are excited to partner with Vance Street as we look toward our next chapter of growth,” said Mr. Ring. “Vance Street’s highly relevant investing and operating experience in the medical manufacturing space made them the ideal partner to help Applied execute on the exciting growth we see across our customer base.”
 
Brian Martin, Managing Partner at Vance Street, commented, “Dave Ring has built an industry leading and highly differentiated business that is well positioned across the fastest growing medical end markets. We’re excited to support the Applied team during this next chapter of growth.”
 
Vance Street Capital’s other medical investments in Fund II include Motion Dynamics, a leading manufacturer of wire-based micro-components and sub-assemblies found in micro-catheters, Adam Spence Vascular Solutions, a designer and manufacturer of high pressure braided tubing and extrusions for the cardiovascular end markets and A&E Medical, a leading medical device OEM focused on single-use products used in cardiovascular procedures.
 
“Applied Plastics is an ideal opportunity for Vance Street to leverage our operating experience and network within medical manufacturing to continue to build on the world-class and highly-proprietary coatings capabilities Applied has built over the past 25 years,” said Mike Janish, Managing Partner at Vance Street.
 
“We’ve known and admired Applied since our prior involvement with Avalon Laboratories, a medical vascular catheter manufacturer, and are thrilled to have the opportunity to partner with a best in class supplier to the medical catheter industry,” said John LeRosen, Partner at Vance Street.
 
Paul Hastings LLP acted as legal advisor to Vance Street Capital. Senior debt was provided by BMO Sponsor Finance and Neuberger Berman. Raymond James and Sullivan & Worcester LLP served as financial advisor and legal advisor, respectively, to Applied. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-01-31 10:14:00 [updated_at] => 2019-01-31 10:25:17 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["305917","305910","305608","305409","305174","304187","304105","303297","302686","300728","298721","296461","300632","300394","290585"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) [4] => Content Object ( [className] => Content [contentLinks] => Array ( ) [belongsTo] => [contentIssue] => [id] => 307577 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => contents [content_type_id] => 2487 [resource_id] => 0 [author_id] => 0 [primary_issue_slug] => [author_name] => {"name":"PR Newswire","title":""} [magazine_id] => 6 [layout_id] => 0 [primary_image] => 182612 [primary_image_old] => [slider_image_id] => 182612 [banner_image] => 0 [title] => Francisco Partners Acquires Qualcomm Life [short_title] => [summary] => Acquisition positions standalone company to focus on growth opportunities. [slug] => francisco-partners-acquires-qualcomm-life [body] => Francisco Partners ("FP"), a technology-focused private equity firm, today announced it has acquired Qualcomm Life Inc. a wholly owned subsidiary of Qualcomm Incorporated that offers end-to-end medical device connectivity across the continuum of care.
 
Qualcomm Life will be separated from Qualcomm, be renamed as Capsule Technologies Inc. ("CapsuleTech"), and continue operating its two distinct business segments: Capsule (a leading provider of medical device connectivity solutions for hospitals) and 2net (a medical grade mobile connectivity platform).
 
"Francisco Partners' deep experience in healthcare technology and proven track record in nurturing and growing technology businesses will enable CapsuleTech's loyal base of employees to continue delivering innovation," said Duane Nelles, Senior Vice President of Corporate Development at Qualcomm Incorporated. "We look forward to our partnership with the FP team as they grow CapsuleTech as an independent entity."
 
"FP's acquisition will help Qualcomm Life (now CapsuleTech) continue to deliver market-leading products and services to its world-class customer base," said Rick Valencia, former President of Qualcomm Life, who will support CapsuleTech as an advisor in its transition to a standalone company.
 
Capsule is a leading medical device connectivity platform that connects medical devices to clinical information systems in over 2,000 hospitals in approximately 40 countries. Through Capsule's connected devices, networking solutions, and intelligent software applications, hospitals can capture and visualize clinical data to monitor patient health and improve patient care.
 
"Capsule is a key enabler of the digital hospital and is a trusted choice among hospital clinicians, IT administrators, and healthcare IT vendors," said Chris Adams, Partner with Francisco Partners. "As hospitals continue to adopt data-driven approaches to managing patient care, Capsule stands to benefit by serving as a centralized connectivity hub for clinical information. We are excited to partner with Capsule and to help the team capitalize on new innovations in device technology and software applications."
 
2net provides wireless mobile device connectivity via cloud-based solutions so biometric information is easily accessible by device users, healthcare providers, and payors. 2net's customers include leading health insurance payors, pharmaceutical companies, and medical device manufacturers.
 
"Capsule and 2net will continue to drive increased focus on their respective customers, deliver mission-critical solutions and provide exceptional service," said Justin Chen, Vice President with Francisco Partners. "We look forward to supporting the talented employees and management team going forward."
 
Centerview Partners served as financial advisor and DLA Piper LLP served as legal advisor to Qualcomm Incorporated. Kirkland & Ellis LLP served as legal advisor to Francisco Partners. Terms of the transaction were not disclosed. [views] => 0 [published] => 1 [status] => 3 [priority] => 0 [publish_date] => 2019-02-11 09:29:00 [updated_at] => 2019-02-11 09:48:21 [last_updated_author] => 199474 [uploaded_by] => 199474 [user_role_id] => 0 [custom_fields] => [] [custom_fields_old] => [splitcontent] => 1 [content_url] => [related_content_ids] => ["304187","298715","306990","305917","305910","305608","305409","305174","304105","303297","302686","294222","307191","294052","306705","301747"] [is_show_company_name] => [created_at] => 2019-04-09 04:36:23 ) ) [relatedSearches] => Array ( [0] => Taxonomy Object ( [className] => Taxonomy [id] => 58572 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [taxonomy_tag] => mechanical ) [1] => Taxonomy Object ( [className] => Taxonomy [id] => 65871 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [taxonomy_tag] => incubator ) [2] => Taxonomy Object ( [className] => Taxonomy [id] => 59150 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [taxonomy_tag] => ceo ) [3] => Taxonomy Object ( [className] => Taxonomy [id] => 61179 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [taxonomy_tag] => acquisition ) ) [contentTaxonomy_knowledge-center] => Array ( [0] => Taxonomy Object ( [className] => Taxonomy [id] => 65661 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [content_taxonomy_id] => 6513863 [slug] => surgical [child_of] => 65655 [ignore_flag] => 0 [up3_tag] => [up2_tag] => Knowledge Center [up1_tag] => Device Sectors [taxonomy_tag] => Surgical [up3_id] => [up2_id] => 7963 [up1_id] => 65655 [taxonomy_id] => 65661 [depth] => 2 ) [1] => Taxonomy Object ( [className] => Taxonomy [id] => 28724 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [content_taxonomy_id] => 6513865 [slug] => contract-manufacturing [child_of] => 8021 [ignore_flag] => 0 [up3_tag] => [up2_tag] => Knowledge Center [up1_tag] => Supply Chain [taxonomy_tag] => Contract Manufacturing [up3_id] => [up2_id] => 7963 [up1_id] => 8021 [taxonomy_id] => 28724 [depth] => 2 ) ) [formattedTitle] => Seisa Medical Acquires Burpee MedSystems [taxonomy_keywords] => Array ( [0] => Taxonomy Object ( [className] => Taxonomy [id] => 24551 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => Manufacturing [slug] => manufacturing [child_of] => 24495 ) [1] => Taxonomy Object ( [className] => Taxonomy [id] => 24592 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => Outsourcing [slug] => outsourcing [child_of] => 24495 ) [2] => Taxonomy Object ( [className] => Taxonomy [id] => 50352 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => medical device [slug] => medical-device [child_of] => 24495 ) [3] => Taxonomy Object ( [className] => Taxonomy [id] => 56740 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => fda [slug] => fda [child_of] => 24495 ) [4] => Taxonomy Object ( [className] => Taxonomy [id] => 57364 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => innovation [slug] => innovation [child_of] => 24495 ) [5] => Taxonomy Object ( [className] => Taxonomy [id] => 57635 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => stents [slug] => stents [child_of] => 24495 ) [6] => Taxonomy Object ( [className] => Taxonomy [id] => 57973 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => machining [slug] => machining [child_of] => 24495 ) [7] => Taxonomy Object ( [className] => Taxonomy [id] => 57991 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => implantable [slug] => implantable [child_of] => 24495 ) [8] => Taxonomy Object ( [className] => Taxonomy [id] => 57998 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => quality [slug] => quality [child_of] => 24495 ) [9] => Taxonomy Object ( [className] => Taxonomy [id] => 58188 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => class iii [slug] => class-iii [child_of] => 24495 ) [10] => Taxonomy Object ( [className] => Taxonomy [id] => 58332 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => engineering [slug] => engineering [child_of] => 24495 ) [11] => Taxonomy Object ( [className] => Taxonomy [id] => 58470 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => fda approval [slug] => fda-approval [child_of] => 24495 ) [12] => Taxonomy Object ( [className] => Taxonomy [id] => 58572 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => mechanical [slug] => mechanical [child_of] => 24495 ) [13] => Taxonomy Object ( [className] => Taxonomy [id] => 58829 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => design [slug] => design [child_of] => 24495 ) [14] => Taxonomy Object ( [className] => Taxonomy [id] => 59080 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => development [slug] => development [child_of] => 24495 ) [15] => Taxonomy Object ( [className] => Taxonomy [id] => 59150 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => ceo [slug] => ceo [child_of] => 24495 ) [16] => Taxonomy Object ( [className] => Taxonomy [id] => 61179 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => acquisition [slug] => acquisition [child_of] => 24495 ) [17] => Taxonomy Object ( [className] => Taxonomy [id] => 61844 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => it [slug] => it [child_of] => 24495 ) [18] => Taxonomy Object ( [className] => Taxonomy [id] => 63660 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => medical [slug] => medical [child_of] => 24495 ) [19] => Taxonomy Object ( [className] => Taxonomy [id] => 63679 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => manufacturer [slug] => manufacturer [child_of] => 24495 ) [20] => Taxonomy Object ( [className] => Taxonomy [id] => 63696 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => manufacture [slug] => manufacture [child_of] => 24495 ) [21] => Taxonomy Object ( [className] => Taxonomy [id] => 64227 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => company [slug] => company [child_of] => 24495 ) [22] => Taxonomy Object ( [className] => Taxonomy [id] => 64675 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => market [slug] => market [child_of] => 24495 ) [23] => Taxonomy Object ( [className] => Taxonomy [id] => 65670 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => regulatory [slug] => regulatory [child_of] => 24495 ) [24] => Taxonomy Object ( [className] => Taxonomy [id] => 65871 [pageNumber] => [offset] => [totalPages] => [last_query] => [last_sql] => [show_errors] => 1 [databaseServer] => Array ( [key] => master [host] => 172.24.16.232 [user] => rodpub_beta [pass] => MvQQzhse92k58yA [db] => rodpub_beta ) [tableName] => taxonomy [tag] => incubator [slug] => incubator [child_of] => 24495 ) ) )